Molecular Pharmagroup — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

Molecular PharmaGroup is a private, commercial-stage company operating as a 503B outsourcing facility, a regulatory category created by the Drug Quality and Security Act of 2013. Its business model is service-oriented, providing hospitals and clinics with reliable access to sterile, compounded generic drugs, particularly those in shortage. The company differentiates itself by voluntarily submitting to FDA oversight and cGMP standards, which exceed typical pharmacy compounding regulations. Its core value proposition is ensuring a high-quality, compliant supply of essential sterile medications for acute and institutional care settings.

Generic Drugs

Technology Platform

cGMP-compliant sterile manufacturing facility with state-of-the-art cleanrooms, adhering to USP <797> and <800> standards. Quality platform relies on independent third-party testing for sterility, endotoxin, and potency, with full batch documentation via Certificates of Analysis.

Opportunities

Persistent drug shortages, particularly in generic sterile injectables, create a steady demand for reliable 503B suppliers.

The healthcare industry's shift toward FDA-overseen outsourcing facilities for risk mitigation provides a strong regulatory tailwind for compliant companies like Molecular PharmaGroup.

Risk Factors

The company faces significant regulatory risk from FDA inspections and evolving USP standards.

Its market is volatile, as demand is tied to drug shortages that can resolve abruptly, and it operates in an increasingly competitive 503B landscape with potential price pressure.

Competitive Landscape

Molecular PharmaGroup competes within the 503B outsourcing facility sector, which includes other private companies like Athenex Pharmaceutical Division (formerly QuVa Pharma), Pentec Health, and Central Admixture Pharmacy Services (CAPS). Competition is based on quality reputation, regulatory compliance, product portfolio breadth, reliability, and price.

More companies in Small Molecule Drugs →More companies in United States →